AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
“We made another investment the morning after the war with Iran began”
2
Intel to begin foundry layoffs in July, but uncertainty hangs over Israel amid wartime reality
3
Cyberattacks against Israel surge 700% in two days, says Radware
4
Google’s $32 billion acquisition of Wiz draws antitrust attention
5
Combat-ready and camera-eyed: The X-Intra drone joins Israel’s arsenal
More news

Teva Pharmaceutical Industries

6 stories about Teva Pharmaceutical Industries
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
מנכ"ל טבע החדש קור שולץ 2

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
default image

Teva Sells IUD Business for $1.1 Billion

12.09.17|Lilach Baumer
Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles